Camrelizumab plus Apatinib

Phase 3Small molecule

PPeking University Cancer Hospital & Institute

Camrelizumab plus Apatinib is one of 151 small molecule programs targeting First-line Treatment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-Line TreatmentRecruiting

Locally-Advanced Rectal CancerRecruiting

Esophageal CancerRecruiting

Hepatocellular CarcinomaNot yet recruiting

Nab-PaclitaxelRecruiting

First-Line TreatmentPhase 2

Recruiting

Locally-Advanced Rectal CancerPhase 3

Recruiting

Esophageal CancerPhase 2

Recruiting

Hepatocellular CarcinomaPhase 2

Not yet recruiting

Nab-PaclitaxelPhase 2

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Camrelizumab plus Apatinib

PPeking University Cancer Hospital & Institute

Phase 3

1 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Ibrance

Pfizer

Preclinical

1 4

Viread

Gilead

Preclinical

1 5

Sovaldi

Gilead

Preclinical

1 6

Hepsera

Coreg

2 8

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 9

Doptelet

AAkarx

Preclinical

1 10

Valemetostat

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

First-Line Treatment

NCT06360042

Q4 2028

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT07314372

Q4 2029

Phase 3Recruiting

Locally-Advanced Rectal Cancer

NCT06229041

Phase 2Recruiting

Esophageal Cancer

NCT06869226

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma

Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT07314372·86 enrolled

Lung Cancer1 trial

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer

Unknown status·HHenan Cancer Hospital·Phase 2·NCT04901754·38 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Unknown status·PPeking University·Phase 2·NCT04609176·64 enrolled

Liver Transplant1 trial

Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant

Unknown status·ZZhejiang University·Phase 1/2·NCT04035876·120 enrolled

Unresectable1 trial

A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC

Unknown status·WWan-Guang Zhang·Phase 2·NCT05839197·38 enrolled

4 more indications

First-line Treatment1 trial

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06360042·111 enrolled

Locally-advanced Rectal Cancer1 trial

Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)

Recruiting·PPeking University Cancer Hospital & Institute·Phase 3·NCT06229041·472 enrolled

Nab-paclitaxel1 trial

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Recruiting·SSun Yat-sen University·Phase 2·NCT04826679·53 enrolled

Esophageal Cancer1 trial

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06869226·283 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Camrelizumab plus Apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Camrelizumab plus Apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Camrelizumab plus Apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Cancer Hospital & Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPeking University Cancer Hospital & Institute

Camrelizumab plus Apatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Lung Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Liver Transplant1 trial

Unresectable1 trial

First-line Treatment1 trial

Locally-advanced Rectal Cancer1 trial

Nab-paclitaxel1 trial

Esophageal Cancer1 trial

References

Drug Info

Quick Facts

Related News